Therefore, further studies are needed to clarify the effects of other BRAF mutations in ovarian cancer, and to completely describe the mutation profile of KRAS-BRAF signalling in established ovarian cancer cell lines. The gene discussed is KRAS; the disease is ovarian carcinoma.